Evidence map›Paper›PMID 38481848›Full record

ReviewFrontiers in public health2024

Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids.

Albert Dahan, Thomas S Franko, James W Carroll, David S Craig, Callie Crow, Jeffrey L Galinkin, Justin C Garrity, Joanne Peterson, David B Rausch

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
17.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Targeting the Carotid Body Function With Big-KPharmacology research & perspectives · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. [Chemical attacks and accidents : Prehospital management].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Adverse maternal and neonatal effects associated with perinatal xylazine exposure: a systematic review.Journal of perinatology : official journal of the California Perinatal Association · 2026
    Review
  12. Article
  13. Outcompeting opioid-induced respiratory depression.Journal of thoracic disease · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Roles of peripheral and central µAmerican journal of physiology. Lung cellular and molecular physiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Albert Dahan *Department of Anesthesiology, Anesthesia and Pain Research Unit, Leiden University Medical Center, Leiden, Netherlands.
Thomas S Franko *Department of Pharmacy Practice, Wilkes University, Wilkes-Barre, PA, United States.
James W CarrollWhite House Office of National Drug Policy, Washington, DC, United States.
David S CraigDepartment of Pharmacy, Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
Callie CrowDrews 27 Chains, Nocona, TX, United States.
Jeffrey L GalinkinRocky Vista University, Greenwood Village, CO, United States.
Justin C GarrityHealing Transitions, Raleigh, NC, United States.
Joanne PetersonLearn to Cope Inc., Taunton, MA, United States.
David B RauschTennessee Bureau of Investigation, Nashville, TN, United States.
Leiden University Medical Center · NLMoffitt Cancer Center · USRocky Vista University · USThe White House · USWilkes University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Opioid-induced respiratory depression (OIRD) deaths are ~80,000 a year in the US and are a major public health issue. Approximately 90% of fatal opioid-related deaths are due to synthetic opioids such as fentanyl, most of which is illicitly manufactured and distributed either on its own or as an adulterant to other drugs of abuse such as cocaine or methamphetamine. Other potent opioids such as nitazenes are also increasingly present in the illicit drug supply, and xylazine, a veterinary tranquilizer, is a prevalent additive to opioids and other drugs of abuse. Naloxone is the main treatment used to reverse OIRD and is available as nasal sprays, prefilled naloxone injection devices, and generic naloxone for injection. An overdose needs to be treated as soon as possible to avoid death, and synthetic opioids such as fentanyl are up to 50 times more potent than heroin, so the availability of new, higher-dose, 5-mg prefilled injection or 8-mg intranasal spray naloxone preparations are important additions for emergency treatment of OIRDs, especially by lay people in the community. Higher naloxone doses are expected to reverse a synthetic overdose more rapidly and the current formulations are ideal for use by untrained lay people in the community. There are potential concerns about severe withdrawal symptoms, or pulmonary edema from treatment with high-dose naloxone. However, from the perspective of first responders, the balance of risks would point to administration of naloxone at the dose required to combat the overdose where the risk of death is very high. The presence of xylazines as an adulterant complicates the treatment of OIRDs, as naloxone is probably ineffective, although it will reverse the respiratory depression due to the opioid. For these patients, hospitalization is particularly vital. Education about the benefits of naloxone remains important not only in informing people about how to treat emergency OIRDs but also how to obtain naloxone. A call to emergency services is also essential after administering naloxone because, although the patient may revive, they may overdose again later because of the short half-life of naloxone and the long-lasting potency of fentanyl and its analogs.

Indexed as

Drug OverdoseNaloxoneAnalgesics, OpioidFentanylHeroinHumansNarcotic AntagonistsAnalgesics, OpioidFentanylHeroinNaloxoneNarcotic Antagonistsdrug abusefentanylnaloxonenitazeneopioidopioid-induced respiratory depressionxylazine

Identifiers

PMID38481848
PMCPMC10933112
OpenAlexW4392236366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.